Roche scores a notable PhIII success with Tecentriq combo in bladder cancer, but is this another case of too little too late?
Two years after Roche’s PD-L1 drug Tecentriq failed a key test for frontline bladder cancer as a monotherapy, investigators are back with Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
